Keytruda and Zelboraf drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Keytruda (pembrolizumab) and Zelboraf (vemurafenib). Common drug interactions include intracranial pressure increased among females and decreased appetite among males.

The phase IV clinical study analyzes what interactions people have when they take Keytruda and Zelboraf. It is created by eHealthMe based on reports of 27 people who take the same drugs from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Zelboraf?

Zelboraf has active ingredients of vemurafenib. eHealthMe is studying from 8,392 Zelboraf users. Check the latest studies of Zelboraf.

On Jul, 19, 2026

27 people who take Keytruda and Zelboraf together, and have interactions are studied.

Keytruda and Zelboraf drug interactions.

What are the common drug interactions of Keytruda and Zelboraf, by gender? *:

female:

Intracranial pressure increased (high pressure inside the skull and thus in the brain tissue and cerebrospinal fluid)
Retinal vein occlusion (a blockage of the small veins that carry blood away from the retina)
Uveitis (inflammation of the uvea)
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
Ovarian cancer (cancer of ovary)
Rash generalised (rash on most of body parts)
Lung disorder (lung disease)
Malignant neoplasm progression (cancer tumour came back)
Body temperature increased
Burning sensation

male:

Decreased appetite
Fatigue (feeling of tiredness)
Pneumonitis (inflammation of the walls of the alveoli in the lungs)
Adverse drug reaction
Azotaemia (excess of urea or other nitrogenous compounds in the blood)
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Disease progression
Duodenal ulcer
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Hospitalisation

What are the common drug interactions of Keytruda and Zelboraf, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Axillary mass
Blood lactate dehydrogenase increased
Decreased appetite
Fatigue (feeling of tiredness)
Skin reaction
Vascular rupture
Death

40-49:

Intracranial pressure increased (high pressure inside the skull and thus in the brain tissue and cerebrospinal fluid)
Retinal vein occlusion (a blockage of the small veins that carry blood away from the retina)
Uveitis (inflammation of the uvea)
Retinal detachment (a disorder of the eye in which the retina peels away from its underlying layer of support tissue)
Atrioventricular block (heart block)
Cardiac failure
Erythema nodosum (skin inflammation that results in reddish, painful, tender lumps most commonly located in the front of the legs below)
Malignant melanoma stage iv (the cancer has spread to other places in the body, such as the lung, liver, brain, bone, soft tissue, or gastrointestinal (gi) tract. cancer may have spread to places in the skin far away from where it first started)
Malignant neoplasm progression (cancer tumour came back)
Myocarditis (inflammation of heart muscle myocardium)

50-59:

Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
Ovarian cancer (cancer of ovary)
Lung disorder (lung disease)
Periodontitis (inflammation of the tissue around the teeth)
Azotaemia (excess of urea or other nitrogenous compounds in the blood)
Decreased appetite
Fatigue (feeling of tiredness)
Hypoalbuminaemia (levels of albumin in blood serum are abnormally low)
Hypotension (abnormally low blood pressure)
Iridocyclitis (inflammation of the iris and ciliary body of the eye)

60+:

Renal tubular disorder (disease of kidney tubules)
Immunodeficiency
Liver disorder (liver diseases)
Mucosal inflammation (infection of mucous membrane)
Oesophageal ulcer (ulcer of oesophagus)
Rash maculo-papular (red area on the skin that is covered with small confluent bumps)
Malignant neoplasm progression (cancer tumour came back)
Osteosclerosis (an elevation in bone density)
Pneumonitis (inflammation of the walls of the alveoli in the lungs)
Adverse drug reaction

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 14 people, 51.85%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 9 people, 33.33%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 11.11%
Urinary Tract Infection: 2 people, 7.41%
Fungal Infection: 2 people, 7.41%
Diarrhea: 2 people, 7.41%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and Zelboraf?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously